The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adiposity in resectable colorectal cancer.
 
Jessica Hopkins
No Relationships to Disclose
 
David Bigam
No Relationships to Disclose
 
Vickie Baracos
No Relationships to Disclose
 
Dean Eurich
No Relationships to Disclose
 
Rebecca Reif
No Relationships to Disclose
 
Michael B. Sawyer
Stock and Other Ownership Interests - AstraZeneca; Gilead Sciences
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; ipsen; Ipsen; LEO Pharma; Merck; Mylan; Novartis; Novartis Canada Pharmaceuticals Inc; nutricia; pfizer; Sanofi; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Celgene; Immuneering; Ipsen; Ipsen; LEO Pharma; Merck; Nutricia; Pfizer; Yinuoke
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Lilly (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer